A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-149 for the Treatment of Diabetic Macular Edema (DME)
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2018
At a glance
- Drugs THR 149 (Primary)
- Indications Diabetic macular oedema
- Focus Adverse reactions
- Sponsors Oxurion
- 19 Oct 2018 According to an Oxurion media release, initial results from this clinical study are anticipated around the end of the second half of 2019.
- 25 May 2018 According to a Bicycle Therapeutics media release, initial study results are anticipated in mid-2019.
- 25 May 2018 According to a ThromboGenics media release, first patient has been enrolled in this study.